 SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 GLOBE NEWSWIRE -- CytomX Therapeutics, Inc. Nasdaq: CTMX, a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody technology platform, today announced that preclinical data for a conditionally activated interferon alpha-2b IFN-a2b will be presented at the Society for Immunotherapy of Cancer SITC 36th Annual Meeting SITC 2021 taking place November 12-14, 2021, at the Walter E. Washington Convention Center in Washington, D.C. 